Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.58 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4885807 | 0.86 | GAA (0.44) | KDM4EMAPTTP53LMNANPC1 | |
| SCHEMBL4891146 | 0.82 | TDP1 (0.46) | KDM4EMAPTP2RX3TP53HPGD | |
| SCHEMBL27589627 | 0.81 | ALDH1A1 (0.50) | KDM4EMAPTP2RX3TP53FFAR1 | |
| SCHEMBL4675656 | 0.74 | KDM4E (0.51) | KDM4EMAPTHPGDRAB9ASMN1; SMN2 | |
| SCHEMBL893027 | 0.74 | KDM4E (1.00) | KDM4ETP53FFAR1HPGDLMNA | |
| SCHEMBL3822113 | 0.73 | MEN1 (0.46) | KDM4EMAPTP2RX3TP53HPGD | |
| SCHEMBL8126209 | 0.73 | TDP1 (0.41) | KDM4EHPGDALDH1A1NPC1RAB9A | |
| SCHEMBL4467298 | 0.71 | KDM4E (0.58) | KDM4EMAPTP2RX3HPGDALDH1A1 | |
| SCHEMBL31376311 | 0.71 | HCRTR1 (0.46) | KDM4EALDH1A1LMNANPC1RAB9A | |
| SCHEMBL12617433 | 0.70 | PPARG (0.49) | ALDH1A1PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207685-A1 | Heterocyclic Compounds As Modulators Of Peroxisome Proliferator Activated Receptors, Useful For The Treatment And/Or Prevention Of Disorders Modulated By A Ppar | ELI LILLY AND COMPANY (US) | 2008-08-28 | — | — | US | disclosed |
| US-20080207685-A1 | Heterocyclic Compounds As Modulators Of Peroxisome Proliferator Activated Receptors, Useful For The Treatment And/Or Prevention Of Disorders Modulated By A Ppar | ELI LILLY AND COMPANY (US) | 2008-08-28 | — | — | US | disclosed |
| US-20080207685-A1 | Heterocyclic Compounds As Modulators Of Peroxisome Proliferator Activated Receptors, Useful For The Treatment And/Or Prevention Of Disorders Modulated By A Ppar | ELI LILLY AND COMPANY (US) | 2008-08-28 | — | — | US | disclosed |
| US-20080167310-A1 | MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS (PPAR) | GOSSETT LYNN STACY | 2008-07-10 | — | — | US | disclosed |
| US-20080167310-A1 | MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS (PPAR) | GOSSETT LYNN STACY | 2008-07-10 | — | — | US | disclosed |
| US-20080167310-A1 | MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS (PPAR) | GOSSETT LYNN STACY | 2008-07-10 | — | — | US | disclosed |
| US-7345070-B2 | Side effects reduction; Diabetes mellitus, Syndrome X, Type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, atherosclerosis; 3-{4-[2-(2-phenyl-5-methyl-oxazol-4-yl)-ethoxy]-phenyl}-2-methyl-2-phenoxy-propionic acid | ELI LILLY AND COMPANY (US) | 2008-03-18 | — | — | US | disclosed |
| US-7345070-B2 | Side effects reduction; Diabetes mellitus, Syndrome X, Type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, atherosclerosis; 3-{4-[2-(2-phenyl-5-methyl-oxazol-4-yl)-ethoxy]-phenyl}-2-methyl-2-phenoxy-propionic acid | ELI LILLY AND COMPANY (US) | 2008-03-18 | — | — | US | disclosed |
| US-7345070-B2 | Side effects reduction; Diabetes mellitus, Syndrome X, Type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, atherosclerosis; 3-{4-[2-(2-phenyl-5-methyl-oxazol-4-yl)-ethoxy]-phenyl}-2-methyl-2-phenoxy-propionic acid | ELI LILLY AND COMPANY (US) | 2008-03-18 | — | — | US | disclosed |
| US-7282501-B2 | Modulators of peroxisome proliferator activated receptors (PPAR) | ELI LILLY AND COMPANY (US) | 2007-10-16 | — | — | US | disclosed |
| US-20050245584-A1 | Peroxisome proliferator activated receptor agonists | BROOKS DAWN A | 2005-11-03 | — | — | US | disclosed |
| US-6930120-B2 | Oxazolyl-arylproplonic acid derivatives and their use as ppar agonists | ELI LILLY AND COMPANY (US) | 2005-08-16 | — | — | US | disclosed |
| WO-2005051945-A1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS, USEFUL FOR THE TREATMENT AND/OR PREVENTION OF DISORDERS MODULATED BY A PPAR | ELI LILLY AND COMPANY (US) | 2005-06-09 | — | — | WO | disclosed |
| US-20050075378-A1 | Modulators of peroxisome proliferator activated receptors (ppar) | ELI LILLY AND COMPANY | 2005-04-07 | — | — | US | disclosed |
| CN-1578659-A | Modulators of peroxisome proliferator activated receptors (ppar) | LILLY CO ELI (US) | 2005-02-09 | — | — | CN | disclosed |
| US-20040097590-A1 | Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists | BROOKS DAWN ALISA (US) | 2004-05-20 | — | — | US | disclosed |
| EP-1401434-A1 | MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS (PPAR) | ELI LILLY AND COMPANY (US) | 2004-03-31 | — | — | EP | disclosed |
| EP-1313716-A1 | OXAZOLYL-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | ELI LILLY AND COMPANY (US) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002100403-A1 | MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS (PPAR) | ELI LILLY AND COMPANY (US) | 2002-12-19 | — | — | WO | disclosed |
| WO-2002016331-A1 | OXAZOLYL-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | ELI LILLY AND COMPANY (US) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075378-A1 | Modulators of peroxisome proliferator activated receptors (ppar) | PPARG, PPARA, PPARD | KDM4E 4175/4885MAPT 2702/4885P2RX3 1603/4885 |
| US-20080167310-A1 | MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS (PPAR) | PPARG, PPARA, PPARD | KDM4E 4175/4885MAPT 2702/4885P2RX3 1603/4885 |
| US-20080207685-A1 | Heterocyclic Compounds As Modulators Of Peroxisome Proliferator Activated Receptors, Useful For The Treatment And/Or Prevention Of Disorders Modulated By A Ppar | PPARG, PPARD, PPARA | KDM4E 4016/4885MAPT 3142/4885P2RX3 1934/4885 |
| US-20040097590-A1 | Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists | PPARA, PPARG, PPARD | KDM4E 3306/4885MAPT 4494/4885P2RX3 133/4885 |
| US-20050245584-A1 | Peroxisome proliferator activated receptor agonists | PPARG, PPARA, PPARD | KDM4E 3194/4885MAPT 4575/4885P2RX3 338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.